Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 1997

View Archived Issues

Tokyo Tanabe discloses beta3-adrenoceptor agonists

Protein tyrosine kinase inhibitors from Kyowa Hakko

Novel antitumor agents from Kyowa Hakko

Prokinetic agents disclosed by Zeria

SKB reports new delta-receptor agonists/antagonists

New antibiotics from BTG

Chiroscience investigates MMP/TNF inhibitors

Abbott discloses antibacterial tiacumicin derivatives

New antihistamines in the pipeline at HMR

Biochemie reports new cephalosporins

Ortho reports analgesic drug candidates

Johns Hopkins investigators report new growth factor

Neuroprotective agent described by Taisho

Schering-Plough develops dual PAF and histamine antagonist

Fujisawa characterizes novel antidementia agent

Paracelsian signs CRADA with NCI

Avonex update presented

Long-acting calcium channel blocker proves effective in post-MI patients

Pharmacia & Upjohn's Estring now available on U.S. market

First launch for AccuSite

New approvals for Zagam

Fluasterone enters phase I as breast cancer prevention agent

Integrilin scheduled for review

Generic version of Monistat-7 approved by FDA

February review for Medco's vasodilator combination

Approval sought for Androtest-SL

Genelabs completes first pivotal trial on SLE Rx

Cel-Sci receives award for TB diagnostic

ArQule and Signal expand drug discovery agreement

Lilly and TheraTech drug collaboration

New impotence Rx now available in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...